|1.||Al-Katib, A M: 8 articles (12/2001 - 02/2000)|
|2.||Mohammad, R M: 8 articles (12/2001 - 02/2000)|
|3.||Blumberg, Peter M: 6 articles (04/2015 - 07/2006)|
|4.||Grant, Steven: 6 articles (10/2006 - 05/2002)|
|5.||Kedei, Noemi: 5 articles (04/2015 - 05/2011)|
|6.||Wender, Paul A: 5 articles (10/2014 - 11/2002)|
|7.||Bear, Harry D: 5 articles (11/2013 - 01/2002)|
|8.||Wall, N R: 5 articles (12/2001 - 02/2000)|
|9.||Keck, Gary E: 4 articles (04/2015 - 05/2011)|
|10.||Nakagawa, Yu: 4 articles (10/2014 - 02/2002)|
04/15/1992 - "Thus, at doses used to treat murine tumors, bryostatin 1 treatment does not affect the clearance of S. "
04/24/2015 - "Bryostatin 1, a complex macrocyclic lactone isolated from Bugula neritina, has been the subject of multiple clinical trials for cancer. "
07/15/2006 - "Bryostatin 1 is currently in clinical trials as a cancer chemotherapeutic agent. "
09/01/1998 - "The development of the NCI human cancer cell line screen, and its application to mechanistic studies through use of COMPARE analyses, are discussed, as is the production of the marine-derived anticancer agent, bryostatin 1, which provides another illustration of a successful approach to solving a supply issue. "
05/01/1996 - "Despite extensive examination of its activities in vitro and anti-tumor effects in vivo, previous studies have failed to document that bryostatin 1 modulates total cellular PKC activity in tumor or normal tissues when administered in vivo. "
07/01/2002 - "Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia."
05/16/2011 - "In U937 human leukemia cells, a second system in which PMA and bryostatin 1 have divergent effects, viz. "
07/01/2002 - "Together, these findings demonstrate that bryostatin 1 can be safely administered as a continuous infusion before and after a split course of HiDAC in patients with refractory leukemia, and identify the bryostatin 1 MTD as 50 microg/m(2) when given by this schedule. "
05/01/1996 - "A similar pattern was observed when bryostatin 1 was incubated with leukemia cells in vitro, raising the possibility that the rapid fall in plasma levels results from intracellular uptake and binding. "
07/25/1991 - "In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells."
|3.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/01/1998 - "Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies."
10/15/2003 - "Bryostatin 1 is known to exhibit in vitro and in vivo activity against chronic lymphocytic leukemia (CLL) cells by inducing their further maturation into plasma-like cells. "
10/15/2003 - "STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1."
04/01/2000 - "Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report."
10/01/1989 - "Peripheral blood cells from nine patients with B-chronic lymphocytic leukemia (B-CLL) were treated in vitro with bryostatin 1 (a macrocyclic lactone derived from a marine invertebrate). "
|4.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
05/01/1998 - "The down-regulation of multidrug resistance (mdr1) gene expression as detected by competitive reverse transcription-PCR and the antitumor activity of bryostatin 1 (Bryo1) are investigated in a newly established cell line from a patient with relapsed diffuse large cell lymphoma (DLCL). "
09/01/1995 - "Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma."
06/01/1995 - "The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma."
05/01/2012 - "In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis. "
05/01/1998 - "Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts."
|5.||Salmonella Infections (Salmonellosis)
|1.||Protein Kinase C
|4.||soblidotin (TZT 1027)
|8.||5'-Nucleotidase (5' Nucleotidase)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Combination Drug Therapy (Combination Chemotherapy)